-Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-.
We report a rash after the first dose of antituberculosis polytherapy which raises questions concerning procedures to be followed.


METHODS
An 8-year-old child presented with a pruritic rash 1.5 hours after the first dose of isoniazide, rifampicine, pyrazinamide and ethambutol was simultaneously administered, which did not recur after successive re-administration of isoniazide and rifampicine. Pyrazinamide, which was re-administered last, induced a recurrence. Slower pyrazinamide re-administration allowed continuation of treatment.


CONCLUSIONS
A protocol for re-administration of the four drugs is suggested.
D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D004338:Drug Combinations; D003875:Drug Eruptions / Q000209:etiology*; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D005076:Exanthema / Q000139:chemically induced*; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D011718:Pyrazinamide / Q000008:administration & dosage / Q000009:adverse effects*; D012008:Recurrence; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*